Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of M6495 in healthy males
NCT03224702Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2017
- Primary completion
- Aug 2018
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing M6495 with Placebo (2 arms). Primary endpoints: Occurrence of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs), Number of Subjects With Injection Site Reactions (ISRs) and 1 more. Started Sep 2017; status: completed.
02
Drugs
isecarosmab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03224702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224702.